Your Article Summary
See Latest ArticlesMental status changes after hematopoietic stem cell transplantation
Cancer, 06/30/09
Chang G et al. - In a study to evaluate and compare neurocognitive changes in pts with chronic myelogenous leukemia (CML) or primary myelodysplastic syndrome (MDS) after allogeneic hematopoietic stem cell transplantation (HSCT) or other therapies, it was concluded that time and diagnosis may be important factors when assessing neurocognitive and other changes. Complaints regarding chemobrain after HSCT merit further study, because deficits may predate initiation of treatment and subsequently may improve. The results could reassure prospective HSCT recipients, because HSCT compared favorably with other treatments when mental status side effects were considered.
Methods- Serial evaluations of attention, concentration, memory, mood, and quality of life were used in a consecutive sample of 106 eligible pts who had CML (n=91) or MDS (n=15) at enrollment and then 12 mos and 18 mos after HSCT or other therapy.
- The 3 evaluations at enrollment, 12 mos, and 18 mos were completed by 98%, 95%, and 89% of surviving participants, respectively.
- Among all pts, there was significant improvement in memory over 18 mos.
- The 45 pts who underwent HSCT (42 pts with CML and 3 with MDS) compared favorably with pts who received other treatment on most measures of neuropsychological function, except they had improved mental health, worse physical function, and more difficulty with coordination and fine motor speed bilaterally.
- Pts with CML overall had improved phonemic fluency.
Related Articles
History of cord blood transplantation
Bone Marrow Transplantation, 10/07/09
Relevance Score: 90%
Preemptive Management of Epstein-Barr Virus Reactivation After Hematopoietic Stem-Cell Transplantation
Transplantation, 10/29/09
Relevance Score: 89%
Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD)
Bone Marrow Transplantation, 10/01/09
Relevance Score: 89%
Outcome of hematopoietic cell transplantation in children with sickle cell disease, a single center's experience
Bone Marrow Transplantation, 10/01/09
Relevance Score: 89%
Allogeneic hematopoietic stem cell transplantation (alloSCT) for chronic myeloid leukemia in the imatinib era; Evaluation of its impact within a subgroup of the randomized German CML Study IV
Blood, 11/20/09
Relevance Score: 88%
Today in BMT/SCT...keeping you current
Receive free subspecialty "5-minute updates" via email
Performing allogeneic and autologous hematopoietic SCT in the outpatient setting: effects on infectious complications and early transplant outcomes
Bone Marrow Transplantation, 12/03/09
Dermatologic manifestations of hematopoietic stem cell transplantation: understanding and management
Expert Review of Dermatology, 12/03/09
Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut points to determine low, intermediate and high risk groups: The flexible HCT-CI is the best predictor of NRM and OS in a population of patients undergoing allo-RIC
Biology of Blood and Marrow Transplantation, 12/03/09